| __timestamp | BioCryst Pharmaceuticals, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 22570000 |
| Thursday, January 1, 2015 | 13047000 | 24378000 |
| Friday, January 1, 2016 | 11253000 | 26621000 |
| Sunday, January 1, 2017 | 13933000 | 28653000 |
| Monday, January 1, 2018 | 29514000 | 37734000 |
| Tuesday, January 1, 2019 | 37121000 | 41884000 |
| Wednesday, January 1, 2020 | 67929000 | 64435000 |
| Friday, January 1, 2021 | 118818000 | 57483000 |
| Saturday, January 1, 2022 | 159371000 | 70062000 |
| Sunday, January 1, 2023 | 213894000 | 52790000 |
Data in motion
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, Ligand Pharmaceuticals Incorporated and BioCryst Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses. Ligand Pharmaceuticals has maintained a relatively stable SG&A cost, averaging around $42.7 million annually, with a peak in 2022. In contrast, BioCryst Pharmaceuticals has seen a dramatic increase, with expenses growing by over 280% from 2014 to 2023, peaking at $213.9 million in 2023. This significant rise in BioCryst's SG&A costs could indicate aggressive expansion or increased operational inefficiencies. Meanwhile, Ligand's more controlled expense growth suggests a strategic approach to cost management. As investors and stakeholders evaluate these companies, understanding their SG&A trends provides valuable insights into their operational strategies and financial health.
Insmed Incorporated and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Bio-Techne Corporation vs BioCryst Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Pharming Group N.V. and Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and BioCryst Pharmaceuticals, Inc.
PTC Therapeutics, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Perrigo Company plc and Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of ImmunityBio, Inc. and Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Wave Life Sciences Ltd.
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Celldex Therapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs BioCryst Pharmaceuticals, Inc.